Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03218761

POTS NET mRNA Functional Correlation With NET Activity

DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

13 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

About this study

Work from The Baker Institute in Melbourne, Australia has shown that there can be significant epigenetic modification of the Norepinephrine Transporter (NET). DNA Acetylation can be responsible for significant down-regulation of transcription. NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses.Very low levels of NET can produce a hyperadrenergic phenotype and can "cause" Postural Tachycardia Syndrome (POTS). The Baker Institute researchers have started using quantified NET mRNA levels from a peripheral blood sample to assess NET availability. This is a huge advance due to its simplicity, in contrast to a prior method which involved a vein biopsy to look at the level of protein expression.

In this protocol, the investigators seek to assess whether these NET messenger RNA (mRNA) levels correlate with NET function. When NET transports NE back into presynaptic neurons, a high percentage gets converted to a metabolite (DHPG) and then released into the blood stream. Therefore, the ratio of DHPG:NE ratio is decreased with reduced NET activity. The investigators will assess this DHPG:NE ratio in POTS patients and control subjects from both plasma and urine samples.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • Postural Tachycardia Syndrome
  • Previously diagnosed with POTS
  • Control Subjects
  • Not diagnosed with POTS
  • Age between 13-80 years
  • Male and female subjects are eligible.
  • Able and willing to provide informed consent (if ≥18 years) or assent with parental consent (if age 13-17 years)

Exclusion criteria

  • • Inability to give, or withdrawal of, informed consent
  • Use of serotonin-norepinephrine reuptake inhibitors (SNRI) or NET inhibitors within 1 month

o These drugs pharmacologically block NET activity

  • Use of Tricyclic antidepressants within 1 week

o Many tricyclic antidepressants pharmacologically block NET activity

  • Other factors which in the investigator's opinion would prevent the subject from completing the protocol.

Treatment and study plan

NET mRNA level

Diagnostic Test

quantification of mRNA to the Norepinephrine Transporter (NET)

Plasma catechols

Diagnostic Test

plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols

Urine Catechols

Diagnostic Test

urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols

Primary outcomes

  1. Supine Plasma DHPG:NE correlation

    Time frame: 1 day

    NET mRNA above and below median supine plasma DHPG:NE

Secondary outcomes

  1. Standing Plasma DHPG:NE correlation

    Time frame: 1 day

    NET mRNA above and below median standing plasma DHPG:NE

  2. Urine DHPG:NE correlation

    Time frame: 1 day

    NET mRNA above and below median urine DHPG:NE

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Collaborators

  • Dysautonomia International
  • University of Calgary

Registry information

Official study title

Validation of Norepinephrine Transporter (NET) mRNA as a Measure of Functional NET Expression in Postural Tachycardia Syndrome (POTS)

Important dates

Study start
2017
Primary completion
2029
Study completion
2029
First posted
Jul 17, 2017
Registry last updated
Oct 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.